Fundraising Fox

Vianovatx

Oakland, US · Founded 2020 · Delaware corporation · 2 known investors

Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections. The company focuses on infections with high prevalence and severe illness potential, serving patients with unmet treatment needs across multiple viral categories.

Founders & leadership

DG
Donald GanemNamed on SEC filing
BL
Benjamine LiuNamed on SEC filing
IZ
Ilan ZipkinNamed on SEC filing

Board

JJJoseph Jimenez
Joseph JimenezinBoard directorInvestor at Aditum Bio

Investors · 2

Reported raises · per SEC filings

Form D private placements

$5M disclosed across 1 round · 2021

$5MraisedSep 2021 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Donald GanemExecutive Officer, Director
  • Joseph JimenezDirector
  • Benjamine LiuDirector
  • Ilan ZipkinDirector
Offering amount
$5M
Amount sold
$5M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Companies competing with Vianovatx for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Vianovatx do?
Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections. The company focuses on infections with high prevalence and severe illness potential, serving patients with unmet treatment needs across multiple viral categories.
Who are Vianovatx's investors?
Vianovatx's investors include Aditum Bio, PMV.
How much funding has Vianovatx raised?
Vianovatx has disclosed $5M raised across 1 round.
Where is Vianovatx headquartered?
Vianovatx is headquartered in Oakland, US.